Kestra Advisory Services
CAI icon

Kestra Advisory Services’s Caris Life Sciences CAI Stock Holding History

Kestra Advisory Services’s Portfolio CAI Stock Details CAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$882K Buy
28,801
+711
+3% +$16K ﹤0.01% 2056
2026
Q2 		$501K Buy
+28,090
New +$503K ﹤0.01% 2347

Other funds holding CAI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Los Angeles Capital Management
Los Angeles Capital Management Los Angeles, California $29.2B AUM 33.64% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Amundi
Amundi Paris, France $496B AUM 35.36% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $144B AUM 22.91% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return
SEI Investments
SEI Investments Oaks, Pennsylvania $113B AUM 26.61% 1-Year Est. Return
Zevenbergen Capital Investments
Zevenbergen Capital Investments Edmonds, Washington $4.37B AUM 52.9% 1-Year Est. Return

Kestra Advisory Services's CAI Position: Q3 2026 in Review

Kestra Advisory Services increased its Caris Life Sciences (CAI) stake by 2.5% in Q3 2026, buying an estimated $16K and bringing the position to 28,801 shares worth $882K. The position accounts for ﹤0.01% of the portfolio, ranked #2056.

Kestra Advisory Services first reported a position in CAI in Q2 2026 and has held it in 2 quarters since. 165 funds tracked by Wall St. Rank hold CAI as of Q3 2026.

  • Kestra Advisory Services held 28,801 shares of Caris Life Sciences worth $882K as of Q3 2026.
  • Kestra Advisory Services bought 711 Caris Life Sciences shares in Q3 2026, an estimated $16K.
  • Caris Life Sciences made up ﹤0.01% of Kestra Advisory Services's portfolio in Q3 2026, its #2056 holding.
  • Kestra Advisory Services first reported a position in Caris Life Sciences in Q2 2026 and has held it in 2 quarters since.
  • 165 funds tracked by Wall St. Rank held Caris Life Sciences as of Q3 2026.

Based on Kestra Advisory Services's 13F filing for Q3 2026, filed 2 Nov 2026.